MX2010007342A - Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido. - Google Patents
Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido.Info
- Publication number
- MX2010007342A MX2010007342A MX2010007342A MX2010007342A MX2010007342A MX 2010007342 A MX2010007342 A MX 2010007342A MX 2010007342 A MX2010007342 A MX 2010007342A MX 2010007342 A MX2010007342 A MX 2010007342A MX 2010007342 A MX2010007342 A MX 2010007342A
- Authority
- MX
- Mexico
- Prior art keywords
- insulin
- formulation
- patient
- formulations
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Abstract
Se describen en la presente formulaciones de insulina inyectables que son capaces de modificar la cantidad de insulina liberada basada en los niveles de glucosa en el tejido del paciente, métodos para hacer y usar estas formulaciones. Las formulaciones se pueden administrar por la vía de la administración subcutánea, intradérmica o intramuscular. En una modalidad preferida, las formulaciones se administran por la vía de la inyección subcutánea. Las formulaciones contienen insulina, un agente oxidante o enzima y un agente reductor o enzima, un diluyente y opcionalmente uno o más agentes de espesamiento. Si un agente de espesamiento está presente en la formulación, el agente de espesamiento incrementa la viscosidad de la formulación después de la administración. De preferencia la formulación contiene una insulina, un diluyente, glucosa oxidasa y peroxidasa. Después de la administración a un paciente, la insulina se libera de las formulaciones como una función del nivel de glucosa en el tejido del paciente, que a su vez mantiene el nivel de glucosa en la sangre del paciente dentro de un intervalo óptimo. La formulación es frecuentemente referida como una formulación "inteligente" puesto que modifica su velocidad de liberación de insulina de acuerdo con las necesidades del paciente en un tiempo particular. En una modalidad preferida, la formulación se diseña para liberar insulina en la circulación sistémica a través del tiempo con un perfil de liberación basal después de la inyección en un paciente. En otra modalidad, la formulación se diseña para liberar insulina en la circulación sistémica a través del tiempo con un perfil de liberación no basal después de la inyección en un paciente, tal como un perfil de liberación de insulina humana regular o un perfil de liberación prandial.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1918708P | 2008-01-04 | 2008-01-04 | |
PCT/US2009/030153 WO2009089181A1 (en) | 2008-01-04 | 2009-01-05 | Insulin formulations for insulin release as a function of tissue glucose levels |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010007342A true MX2010007342A (es) | 2010-08-26 |
Family
ID=40419014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010007342A MX2010007342A (es) | 2008-01-04 | 2009-01-05 | Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090175840A1 (es) |
EP (1) | EP2234644B1 (es) |
JP (1) | JP5352596B2 (es) |
CN (1) | CN101951957A (es) |
AU (1) | AU2009204309B2 (es) |
CA (1) | CA2711561A1 (es) |
HK (1) | HK1149195A1 (es) |
IL (1) | IL206726A0 (es) |
MX (1) | MX2010007342A (es) |
WO (1) | WO2009089181A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010028055A1 (en) * | 2008-09-02 | 2010-03-11 | Biodel, Inc. | Insulin with a basal release profile |
PT2349324T (pt) | 2008-10-17 | 2017-12-06 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
EP2458378B1 (en) * | 2009-07-21 | 2017-12-06 | Sekisui Medical Co., Ltd. | Insulin measurement method |
PL3345593T3 (pl) | 2009-11-13 | 2024-04-08 | Sanofi-Aventis Deutschland Gmbh | Kompozycja farmaceutyczna zawierająca desPro36-eksendynę-4(1-39)-Lys6-NH2 i metioninę |
PE20121362A1 (es) | 2009-11-13 | 2012-10-17 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina |
US8637458B2 (en) | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
AU2011202239C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
WO2011156476A2 (en) * | 2010-06-08 | 2011-12-15 | Biodel Inc. | Insulin with a basal release profile |
WO2012028172A1 (en) | 2010-08-30 | 2012-03-08 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
CN102188367B (zh) * | 2011-01-05 | 2012-11-07 | 山东新时代药业有限公司 | 一种甘精胰岛素注射液及其制备方法 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
AU2012300978B2 (en) | 2011-08-29 | 2017-04-27 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
CN103191417A (zh) * | 2012-01-05 | 2013-07-10 | 四川大学 | 载有胰岛素聚集体的长效控制血糖浓度的药物控释体系及制备方法 |
AU2013346624B2 (en) | 2012-11-13 | 2018-08-09 | Adocia | Quick-acting insulin formulation including a substituted anionic compound |
WO2014096985A2 (en) | 2012-12-19 | 2014-06-26 | Wockhardt Limited | A stable aqueous composition comprising human insulin or an analogue or derivative thereof |
BR112015013223A2 (pt) * | 2012-12-26 | 2017-07-11 | Wockhardt Ltd | composição farmacêutica |
ES2709339T3 (es) | 2013-04-03 | 2019-04-16 | Sanofi Sa | Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada |
CN104587455A (zh) * | 2013-10-31 | 2015-05-06 | 江苏万邦生化医药股份有限公司 | 一种胰岛素制剂 |
SG11201607936QA (en) * | 2014-04-25 | 2016-11-29 | Sanofi Sa | New administration routes of insulin, insulin analogs or derivatives of insulin |
WO2016001862A1 (en) | 2014-07-04 | 2016-01-07 | Wockhardt Limited | Extended release formulations of insulins |
EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
CN104688677B (zh) * | 2015-02-05 | 2018-02-09 | 通化东宝药业股份有限公司 | 一种稳定的甘精胰岛素注射液及其制备方法 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
CA3045882A1 (en) | 2016-12-05 | 2018-06-14 | North Carolina State University | Core-shell microneedle devices and uses thereof |
CN109464657A (zh) * | 2018-11-26 | 2019-03-15 | 常州工程职业技术学院 | 一种嵌段共聚物载胰岛素控制释放的方法 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2143590A (en) * | 1936-09-26 | 1939-01-10 | Univ Alberta | Insulin preparation and process of producing crystals of insulin |
US2626228A (en) * | 1945-05-17 | 1953-01-20 | Novo Terapeutisk Labor As | Method of producing crystalline insulin |
US2819999A (en) * | 1953-11-13 | 1958-01-14 | Novo Terapeutisk Labor As | Process for crystallization of insulin using freeze dried insulin as seeding material |
US3649456A (en) * | 1969-09-08 | 1972-03-14 | Rohm & Haas | Separation of polypeptide substances with macroreticular resins |
FR2224175B1 (es) * | 1973-04-04 | 1978-04-14 | Isf Spa | |
US4153689A (en) * | 1975-06-13 | 1979-05-08 | Takeda Chemical Industries, Ltd. | Stable insulin preparation for nasal administration |
US4211769A (en) * | 1977-08-24 | 1980-07-08 | Takeda Chemical Industries, Ltd. | Preparations for vaginal administration |
US4377482A (en) * | 1978-04-28 | 1983-03-22 | Salk Institute For Biological Studies | Mobile phase for liquid chromatography |
US4196196A (en) * | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
US4272398A (en) * | 1978-08-17 | 1981-06-09 | The United States Of America As Represented By The Secretary Of Agriculture | Microencapsulation process |
JPS55138393A (en) * | 1979-04-13 | 1980-10-29 | Shionogi & Co Ltd | Semisynthesis of insulin |
US4343898A (en) * | 1980-02-11 | 1982-08-10 | Novo Industri A/S | Process for preparing esters of human insulin |
US4364385A (en) * | 1981-03-13 | 1982-12-21 | Lossef Steven V | Insulin delivery device |
KR890000664B1 (ko) * | 1981-10-19 | 1989-03-22 | 바리 안소니 뉴우샘 | 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법 |
US4459226A (en) * | 1982-02-26 | 1984-07-10 | Eli Lilly And Company | Process for recovering insulin |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4946828A (en) * | 1985-03-12 | 1990-08-07 | Novo Nordisk A/S | Novel insulin peptides |
US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
EP0318512B1 (en) * | 1986-08-18 | 1998-06-17 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
USRE35862E (en) * | 1986-08-18 | 1998-07-28 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
DE3779221D1 (de) * | 1986-08-19 | 1992-06-25 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen. |
US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
GB8723846D0 (en) * | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
US5006343A (en) * | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
US5188837A (en) * | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU1442592A (en) * | 1991-02-20 | 1992-09-15 | Nova Pharmaceutical Corporation | Controlled release microparticulate delivery system for proteins |
US5492112A (en) * | 1991-05-20 | 1996-02-20 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
CA2070061C (en) * | 1991-06-07 | 2004-02-10 | Shigeyuki Takama | Physiologically active polypeptide-containing pharmaceutical composition |
US6063910A (en) * | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
US5329976A (en) * | 1991-12-09 | 1994-07-19 | Habley Medical Technology Corporation | Syringe-filling and medication mixing dispenser |
JP3121080B2 (ja) * | 1991-12-19 | 2000-12-25 | アール・ピー・シーラー コーポレイション | カプセル封入用溶液 |
US5352461A (en) * | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5785049A (en) * | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
US5888477A (en) * | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
US5747445A (en) * | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
IS1796B (is) * | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
EP0804174A4 (en) * | 1993-07-21 | 1998-09-09 | Univ Kentucky Res Found | MULTI-CHAMBER HARD CAPSULES WITH CONTROLLED DELIVERY CHARACTERISTICS |
US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
CA2171424C (en) * | 1993-09-17 | 2002-06-04 | Svend Havelund | Acylated insulin |
US5484606A (en) * | 1994-01-24 | 1996-01-16 | The Procter & Gamble Company | Process for reducing the precipitation of difficulty soluble pharmaceutical actives |
ES2218543T3 (es) * | 1994-03-07 | 2004-11-16 | Nektar Therapeutics | Procedimiento y preparacion para la administracion de insulina por via pulmonar. |
US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US6395744B1 (en) * | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5547929A (en) * | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
CA2206053A1 (en) * | 1994-12-01 | 1996-06-06 | Toyama Chemical Co., Ltd. | Novel 2,3-diketopiperazine derivatives or their salts |
US5901703A (en) * | 1995-02-06 | 1999-05-11 | Unisia Jecs Corporation | Medicine administering device for nasal cavities |
US5653961A (en) * | 1995-03-31 | 1997-08-05 | Minnesota Mining And Manufacturing Company | Butixocort aerosol formulations in hydrofluorocarbon propellant |
US6428771B1 (en) * | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
US5653987A (en) * | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
CA2236579C (en) * | 1995-11-13 | 2009-06-30 | Minimed, Inc. | Methods and compositions for the delivery of monomeric proteins |
DE19545257A1 (de) * | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
USRE37053E1 (en) * | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US6503480B1 (en) * | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6254854B1 (en) * | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
US5898028A (en) * | 1997-03-20 | 1999-04-27 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
WO1999016417A1 (en) * | 1997-10-01 | 1999-04-08 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
US6451346B1 (en) * | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
US6444226B1 (en) * | 1999-06-29 | 2002-09-03 | Pharmaceutical Discovery Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
MXPA02004193A (es) * | 1999-10-29 | 2002-12-13 | Inhale Therapeutic Syst | Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas. |
ES2305057T3 (es) * | 2000-02-28 | 2008-11-01 | Pharmakodex Limited | Dispositivo para la administracion de farmacos orales. |
US6432383B1 (en) * | 2000-03-30 | 2002-08-13 | Generex Pharmaceuticals Incorporated | Method for administering insulin |
US7316999B2 (en) * | 2000-06-02 | 2008-01-08 | Novo Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
GB0129489D0 (en) * | 2001-12-10 | 2002-01-30 | Quadrant Healthcare Uk Ltd | Sustained-release compositions |
US7255102B2 (en) * | 2002-02-01 | 2007-08-14 | Generex Pharmaceuticals Inc. | Metered dose spray device for use with macromolecular pharmaceutical agents such as insulin |
EP1506003A1 (en) * | 2002-05-07 | 2005-02-16 | Novo Nordisk A/S | Soluble formulations comprising insulin aspart and insulin detemir |
DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
DE10235168A1 (de) * | 2002-08-01 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Verfahren zur Reinigung von Preproinsulin |
WO2004041118A2 (en) * | 2002-10-31 | 2004-05-21 | Umd, Inc. | Therapeutic compositions for drug delivery to and through covering epithelia |
AU2003261633A1 (en) * | 2003-02-12 | 2004-09-06 | R And P Korea Co., Ltd. | Solvent system of hardly soluble drug with improved elution rate |
BRPI0414539B8 (pt) * | 2003-09-19 | 2021-05-25 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
US7192919B2 (en) * | 2004-01-07 | 2007-03-20 | Stelios Tzannis | Sustained release compositions for delivery of pharmaceutical proteins |
KR100985126B1 (ko) * | 2004-01-12 | 2010-10-05 | 맨카인드 코포레이션 | 제2형 당뇨병에서 혈청 프로인슐린 수치의 감소 방법 |
US20080090753A1 (en) * | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
US20080085298A1 (en) * | 2004-03-12 | 2008-04-10 | Biodel, Inc. | Rapid Mucosal Gel or Film Insulin Compositions |
US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
WO2006088473A2 (en) * | 2004-04-23 | 2006-08-24 | Panduranga Rao Koritala | Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents |
US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US8084420B2 (en) * | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US8093207B2 (en) * | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
US7718609B2 (en) * | 2006-04-12 | 2010-05-18 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
CA2660029A1 (en) * | 2006-08-04 | 2008-02-07 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
-
2009
- 2009-01-05 CN CN2009801058505A patent/CN101951957A/zh active Pending
- 2009-01-05 JP JP2010541583A patent/JP5352596B2/ja not_active Expired - Fee Related
- 2009-01-05 US US12/348,839 patent/US20090175840A1/en not_active Abandoned
- 2009-01-05 WO PCT/US2009/030153 patent/WO2009089181A1/en active Application Filing
- 2009-01-05 EP EP09700220.8A patent/EP2234644B1/en not_active Not-in-force
- 2009-01-05 MX MX2010007342A patent/MX2010007342A/es not_active Application Discontinuation
- 2009-01-05 AU AU2009204309A patent/AU2009204309B2/en not_active Ceased
- 2009-01-05 CA CA2711561A patent/CA2711561A1/en not_active Abandoned
-
2010
- 2010-06-30 IL IL206726A patent/IL206726A0/en unknown
-
2011
- 2011-04-01 HK HK11103347.1A patent/HK1149195A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2009089181A1 (en) | 2009-07-16 |
JP5352596B2 (ja) | 2013-11-27 |
US20090175840A1 (en) | 2009-07-09 |
AU2009204309B2 (en) | 2012-11-22 |
CN101951957A (zh) | 2011-01-19 |
JP2011508786A (ja) | 2011-03-17 |
HK1149195A1 (en) | 2011-11-25 |
EP2234644A1 (en) | 2010-10-06 |
AU2009204309A1 (en) | 2009-07-16 |
IL206726A0 (en) | 2010-12-30 |
CA2711561A1 (en) | 2009-07-16 |
EP2234644B1 (en) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010007342A (es) | Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido. | |
PL385586A1 (pl) | Nowe analogi insuliny o przedłużonym działaniu | |
WO2013123492A3 (en) | Glucose-responsive microgels for closed loop insulin delivery | |
PH12017501910A1 (en) | Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites | |
WO2008124522A3 (en) | Amylin formulations | |
MX2011009174A (es) | Formulaciones de insulina para captacion rapida. | |
EP2829265A3 (en) | Novel formulations for treatment of migraine | |
BR112013032265A2 (pt) | métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano | |
BR0211894A (pt) | Métodod de minimização e de redução dos nìveis médios de glucose, de tratamento de uma condição médica causada por nìveis elevados de glucose no sangue e de redução do valor hba1c em paciente dependente de insulina | |
WO2010056922A3 (en) | Systems and methods for delivery of biologically active agents | |
MX2010003776A (es) | Composiciones de insulina inyectables de accion rapida. | |
NZ710157A (en) | Use of guanethidine for treating hypertension by local vascular delivery | |
EP2676691A3 (en) | Delivery of viscous formulations by needle-free injection | |
WO2010005680A3 (en) | Transdermal local anesthetic patch with injection port | |
MXPA05006634A (es) | Fluidos de dialisis biocompatibles que contienen icodextrinas. | |
EP3488885A3 (en) | Combination of needle hub and shell for use with pen injector | |
WO2013078257A8 (en) | Implantable solid-liquig drug delivery apparatus, formulations, and methods of use | |
WO2005113016A3 (en) | Modulation of glucose-6-phosphatase translocase expression | |
EP2907535A3 (en) | Syringe type pump | |
WO2007105203A3 (en) | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels | |
IN2015DN01454A (es) | ||
MX2021001586A (es) | Plataforma de estabilizacion de cateter, sistemas y metodos. | |
WO2011056447A3 (en) | Methods and kits for preventing hypoglycemia | |
MX2019009922A (es) | Formulaciones a base de aceite para suministro sublingual y bucal. | |
DE60215866D1 (de) | Medikament, enthaltend cyanidin-3-glykosid als wirkstoff gegen fettsucht und diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |